CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 755 enrolled
Drug / intervention
methotrexate +3 moredrug
Likely dose
Not stated in record
Key inclusion· 2
  • ✓Diagnosis of RA for ≤3 years
  • ✓Age ≥18 years at time of diagnosis
Key exclusion· 3
  • ✕Pregnant or lactating women
  • ✕History of chronic infection (hepatitis, pneumonia, or chronic skin infections)
  • ✕Active TB or evidence of latent TB

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00259610
NCT00259610Phase 4Completed
CompareCT.gov

Treatment of Early Aggressive Rheumatoid Arthritis (TEAR)

University of Alabama at Birmingham·interventional·Posted Nov 29, 2005·Updated Jul 17, 2014

In Brief

A Phase 4 clinical trial evaluating methotrexate, sulfasalazine, and 2 other interventions for Rheumatoid Arthritis. Completed, enrolled 755 participants across 1 site.

Detailed Summary

The purpose of this study is to 1)to determine if it is better to treat all early RA patients with methotrexate in combination with hydroxychloroquine plus sulfasalazine or in combination with etanercept or reserve this treatment for patients who do not appropriately respond to methotrexate alone and 2) to determine which combination of methotrexate therapy is better

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesUnited States
CollaboratorsAmgen, Barr Laboratories, Pfizer

Timeline

Phase 4CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 29, 2005
Enrollment StartMay 1, 2004
Primary CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 20.6 years ago

Interventions

methotrexatedrug

varies

sulfasalazinedrug

varies

hydroxychloroquinedrug

varies

etanerceptdrug

varies